Sign In
Buy MNKD
MannKind Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0300 |
| EPS Surprise | 200.00% |
| Revenue estimate | 98.616M |
| Revenue actual | 82.13M |
| Revenue Surprise | -16.72% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0021 |
| EPS Surprise | -94.65% |
| Revenue estimate | 80.161M |
| Revenue actual | 76.527M |
| Revenue Surprise | -4.53% |
| Release date | May 08, 2025 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0400 |
| EPS Surprise | 33.33% |
| Revenue estimate | 78.44M |
| Revenue actual | 78.354M |
| Revenue Surprise | -0.109% |
| Release date | Feb 26, 2025 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0300 |
| Revenue estimate | 74.977M |
| Revenue actual | 76.776M |
| Revenue Surprise | 2.40% |
Last 4 Quarters for MannKind
Below you can see how MNKD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 26, 2025 |
| Price on release | $5.47 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0300 |
| Date | Price |
|---|---|
| Feb 20, 2025 | $5.66 |
| Feb 21, 2025 | $5.76 |
| Feb 24, 2025 | $5.70 |
| Feb 25, 2025 | $5.65 |
| Feb 26, 2025 | $5.47 |
| Feb 27, 2025 | $5.23 |
| Feb 28, 2025 | $5.34 |
| Mar 03, 2025 | $5.13 |
| Mar 04, 2025 | $5.15 |
| 4 days before | -3.36% |
| 4 days after | -5.85% |
| On release day | -4.39% |
| Change in period | -9.01% |
| Release date | May 08, 2025 |
| Price on release | $4.63 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0400 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| May 02, 2025 | $5.00 |
| May 05, 2025 | $4.96 |
| May 06, 2025 | $4.78 |
| May 07, 2025 | $4.85 |
| May 08, 2025 | $4.63 |
| May 09, 2025 | $4.56 |
| May 12, 2025 | $4.81 |
| May 13, 2025 | $4.72 |
| May 14, 2025 | $4.57 |
| 4 days before | -7.40% |
| 4 days after | -1.30% |
| On release day | -1.51% |
| Change in period | -8.60% |
| Release date | Aug 06, 2025 |
| Price on release | $3.47 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0021 |
| EPS surprise | -94.65% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $3.78 |
| Aug 01, 2025 | $3.75 |
| Aug 04, 2025 | $3.92 |
| Aug 05, 2025 | $3.99 |
| Aug 06, 2025 | $3.47 |
| Aug 07, 2025 | $3.43 |
| Aug 08, 2025 | $3.52 |
| Aug 11, 2025 | $3.42 |
| Aug 12, 2025 | $3.66 |
| 4 days before | -8.33% |
| 4 days after | 5.63% |
| On release day | -1.01% |
| Change in period | -3.17% |
| Release date | Nov 05, 2025 |
| Price on release | $6.06 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0300 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $5.55 |
| Oct 31, 2025 | $5.59 |
| Nov 03, 2025 | $5.48 |
| Nov 04, 2025 | $5.48 |
| Nov 05, 2025 | $6.06 |
| Nov 06, 2025 | $5.70 |
| Nov 07, 2025 | $5.63 |
| Nov 10, 2025 | $5.42 |
| Nov 11, 2025 | $5.25 |
| 4 days before | 9.19% |
| 4 days after | -13.37% |
| On release day | -5.94% |
| Change in period | -5.41% |
MannKind Earnings Call Transcript Summary of Q3 2025
Key points for investors: - Record quarter and revenue mix: MannKind reported record Q3 2025 revenues of $82 million (up 17% year-over-year) driven primarily by royalties/manufacturing for Tyvaso DPI. Afrezza net revenue grew 23% to $18.5 million. Non-GAAP net income was $22.4 million ($0.07 per share). - Strategic acquisition: Completed the acquisition of scPharmaceuticals (FUROSCIX), adding a commercial product (FUROSCIX) and a larger commercial footprint. FUROSCIX showed strong adoption in 2025 (Q3 unaudited revenue $19.3M; year-to-date FUROSCIX revenue $47.1M, +95% vs prior year) and >27,000 doses dispensed in Q3 (+153% yoy). FUROSCIX will be included in MannKind’s financials starting Q4 2025. - Near-term regulatory catalysts: Afrezza supplemental BLA (pediatrics) accepted for review with a PDUFA in Q2 2026; sNDA for the FUROSCIX ReadyFlow auto‑injector submitted with an expected PDUFA in Q3 2026. These are highlighted as significant near-term value drivers. - Commercial momentum & collaborations: Tyvaso DPI delivered $59 million in royalty and manufacturing-led revenue (Q3 contribution highlighted as $33M royalties + $26M manufacturing). United Therapeutics expanded the collaboration and is developing a second dry powder molecule with MannKind’s Technosphere platform; a potential Tyvaso DPI bridging study for IPF was discussed by United Therapeutics. - Pipeline & development updates: ICoN‑1 (inhaled clofazimine) Phase III (NTM) enrollment hit an interim target ahead of schedule; INFLO Phase II (nintedanib DPI / MNKD‑201) expected to begin enrollment Q1 2026; MNKD‑701 (bumetanide DPI) advanced into preclinical development. - Commercial and operational plans: MannKind plans to expand field/medical teams (MSLs, key account managers) to support Afrezza pediatric preparation and FUROSCIX hospital/post-discharge adoption (meds-to-bed programs, IDN engagement). Integration of scPharmaceuticals is described as proceeding smoothly. - Financial positioning & capital: To fund the scPharma transaction MannKind used $133M of cash/investments and drew $325M on a 5-year term loan with Blackstone. Management emphasized investing in growth (commercial expansion, pipeline) while addressing short-term obligations (including a convertible stub due March 1, 2026).
